49 results about "Guaiacol Glyceryl Ether" patented technology

The invention relates to a method for producing lignan slow-release micro drop and relative preparation, wherein it comprises active component, and carrier element, slow-release package and quick-release drug layer. The invention uses round technique to prepare high-carrier drug element to be packed and coated with quick-release layer; the slow-release layer uses cellulose ethyl ether; package is processed at fluid condition. The invention can release drug for 12h.

The present invention relates to a kind of medicine composition for treating productive cough, and the medicine composition has ambroxol hydrochloride, guaifenesin and levosalbutamol in certain weight proportion and pharmaceutically acceptable supplementary material. The medicine composition may be prepared into pharmaceutically acceptable preparation forms for treating productive cough caused by chronic bronchitis, asthma, repeatable lower respiratory infection and other respiratory system diseases.

The invention discloses a dextromethorphan hydrobromide and guaiacol glycerin ether oral liquid. The oral liquid contains dextromethorphan hydrobromide, guaiacol glycerin ether, acidifying and alkalizing agents and purified water, wherein the acidifying and alkalizing agents are used for regulating the pH value of the dextromethorphan hydrobromide and guaiacol glycerin ether oral liquid to be 4.0-5.5.

The invention discloses a combination containing r-chlorpheniramine, which is formed by the r-chlorpheniramine and the medicine salt and the other or a plurality of active ingredients or pharmaceutical carriers selected from non-steroidal anti-inflammatory drug, ephedrine alkaloids, coffeine, dextromethorphan hydrobromide, carbetapentane citrate, glyceryl guaiacolate, bromhexine hydrochloride, artificial cow-bezoar, amantadine hydrochloride, aminophylline and zinc gluconate. The orally taken preparation developed from the combination comprises granule, tablet, capsule, dispersible tablet, chewable tablet, effervescent tablet, orally disintegrating tablet, buccal tablet, dry suspension and certain solid formulation.

The invention discloses a composite solid base catalyst which is mainly prepared from the following components in parts by mass: 100 parts of gamma-Al2O3 as a carrier, 0.5-5 parts of a binding agent as a loaded component, 1-25 parts of a magnesium-containing compound, 1-25 parts of a calcium-containing compound, 0.5-5 parts of polyacrylamide and 0.1-2 parts of inorganic base, wherein the binding agent is selected from one of glycerol, starch, methylcellulose, polypropylene glycol, alumina sol and sodium silicate; the magnesium-containing compound is selected from one of MgO, Mg(OH)2, Mg(CO3)2, Mg(OAc)2 and MgCl2; the calcium-containing compound is selected from one of CaO, Ca(OH)2, Ca(CO3)2 and CaCl2; the inorganic base is selected from one of NaOH, KOH, Na2CO3 and K2CO3. The catalyst is used for preparing guaifenesin, is simple and convenient to operate, environmentally friendly, low in energy consumption and high in yield.

The present invention discloses an oral solid preparation containing ambroxal hydrochloride and guaifenesin active components. It is made up by using ambroxol hydrochloride and guaifenesin as active components and auxiliary material according to a certain ratio through a certain preparation process. Said oral solid preparation can be used for mainly curing the diseases of chronic bronchitis and periodic lower respiratory tract infection.

The invention relates to a sustained release preparation taking glyceryl guaiacolate and pseudoephedrine or physiologically acceptable salts thereof as active components, and provides a compound preparation which can overcome cold related symptoms and of which all the active components are slowly released.

The invention discloses a method for analyzing daytime severe cold and flu capsules by high performance liquid chromatography. The daytime severe cold and flu capsules contain acetaminophen, phenylephrine hydrochloride, dextromethorphan hydrobromide and guaifenesin; high performance liquid chromatography analysis conditions are as follows: a chromatographic column adopts an octadecyl silane bonded silica gel column, a sodium octanesulfonate containing 0.1v% triethylamine is used as a mobile phase A, and acetonitrile is used as a mobile phase B. The method can efficiently and simultaneously detect four effective components in the daytime severe cold and flu capsules; furthermore, the method is easy to operate, high in analysis speed, high in repetitiveness and extremely high in specificity; the product quality of a daytime severe cold and flu capsule preparation can be relatively efficiently and comprehensively controlled.

The invention provides a compound dextromethorphan hydrobromide syrup and a preparation method for the same. The compound dextromethorphan hydrobromide syrup is used for eliminating phlegm in cough, and comprises dextromethorphan hydrobromide, guaifenesin and a bacillus natto extract. The syrup improves the safety of medication and is especially suitable for children, reduces bitter taste and the consumption of a flavouring agent, improves the stability, especially the colour of solution and the stability of the colour, and improves the curative effect on the cough caused by cold and bronchitis simultaneously.

The present invention is one kind of compound licorice preparation and its preparation process. The compound licorice preparation is orally taken gel, coated tablet, capsule or dripping pill prepared with licorice extractum, compounding camphor tincture, guaiacol, glycerin ether and supplementary material. Compared with available technology, the present invention has the advantages of high curative effect, easy taking and high bioavailability. It is used in trachitis, pharyngolaryngitis, etc. The present invention also provides the preparation process.

The invention discloses an improvement method of a compound glycyrrhiza oral solution production technology. The method comprises the steps of by taking 120ml of extractum glycyrrhizae liquidum, adding 120ml of glycerinum, evenly mixing, adding 500ml of water and diluting; then adding a proper amount of concentrated ammonia solution, and adjusting the pH value to be 8.00-9.00 to obtain an extractum glycyrrhizae liquidum solution; taking 5g of guaiacol glycerol ether, and adding a proper amount of hot water for dissolving to obtain guaiacol glycerol ether solution; adding the guaiacol glycerol ether solution into the extractum glycyrrhizae liquidum solution and stirring at the same time, adding 10g of sodium alginate and 5g of sodium carboxymethyl cellulose, and stirring for dissolving to obtain mixed solution; adding 180ml of compound camphor tineture into the mixed solution, evenly stirring, slowing adding right amount of concentrated ammonia solution, adjusting the pH value of the solution to be 8.00-8.50, and then adding a proper amount of water to form 1000ml of solution; evenly stirring, filtering and carrying sterilization to obtain the compound glycyrrhiza oral solution. The method solves the problems that the compound glycyrrhiza oral solution is easy to precipitate, easily goes bad, is unstable in product quality, etc.

The invention discloses a new synthetic method of guaiacol glycerin ether with a structure as shown in a formula (IV), isopropylidene glycerol-4-methanol with a structure as shown in formula (I) and guaiacol with a structure as shown in a formula (II) are taken as raw materials, Mitsunobu reaction occurs in organic solvent under the effect of triphenylphosphine and diisopropyl azodicarboxylate to generate intermediate product guaiacol isopropylidene glycerol ether with the structure as shown in formual (III); after full reaction, the obtained intermediate product crude product from separation witnesses hydrolysis reaction directly under acid conditions without purification; after separation and purification of the reaction liquid, the target product guaiacol glycerin with the structure as shown in (IV) ether is obtained. The synthetic method of the invention features application of clean raw material with low cost and easy availability, moderate reaction conditions, simple post treatment processes and adaptability to industrialized production.

The invention discloses damp and corrosion prevention valve powder coating. The damp and corrosion prevention valve powder coating is prepared from, by weight, 20-30 parts of novolac epoxy resin, 20-30 parts of bisphenol A epoxy resin, 0.1-0.2 part of guaiacol glyceryl ether, 20-30 parts of kieselguhr, 0.3-0.5 part of nano-cerium oxide, 4-6 parts of alumina sol, 0.5-1 part of polyving akohol, 3-5 parts of aqueous polyurethane emulsion, 1-2 parts of liquid paraffin, 3-5 parts of phenolic curing agent, 0.3-0.5 part of polyaspartic acid and 6-8 parts of coalescing agent. The damp and corrosion prevention valve powder coating has excellent corrosion resistance and levelling property, a formed coating can be well combined with a metallic matrix, the surface is high in smoothness and flatness, peeling and cracking do not occur easily, damp resistance and corrosion resistance are high, and the damp and corrosion prevention valve powder coating is suitable for being used in a humid environment.

The invention relates to a sustained-release preparation which takes guaiacol olycerin ether, pseudoephedrine or salt which is physiologically accepted by pseudoephedrine, and dextromethorphan or salt which is physiologically accepted by dextromethorphan as active ingredients. The sustained-release preparation of the invention not only can fully overcome relative symptoms such as cold and express the effect of synergy of compound medicines, but also the release and absorption of three active ingredients of the sustained-release preparation can reach synchronization, and the expected medicine release behavior can be gained inside and outside a human body. The medicine release behavior can reduce the times of taking medicine (from 4 times each day to 2 times each day, i.e. respectively taking medicine once in the morning and in the evening). The preparation is characterized in that times of taking medicine are reduced, the medicine can be slowly released in the human body, the blood concentration is stable, the fluctuation is small, the bioavailability is high, and the safety is high.

The invention provides a robitussin oral solution and a preparation method thereof. The robitussin oral solution comprises guaiacol glycerol ether, bromhexine hydrochloride, coolsense and polyethylene glycol. The robitussin oral solution provided by the invention has the characteristics of simple preparation technology, good taste, high quality and good stability.

The invention relates to a method for separating guaiacol glyceryl ether enantiomer through a simulated moving bed chromatography technology. The method comprises the steps of: coating cellulose-tris(3,5)-dimethylphenylcarbamate on silica gel as a chiral stationary phase, and n-hexane and ethanol mixture as a mobile phase by adopting a simulated moving bed chromatography system; separating the high-purity single enantiomer of R-(-)-guaiacol glyceryl ether and S-(+)-guaiacol glyceryl ether from racemic guaiacol glyceryl ether, wherein the mass fraction can achieve more than 99%. According to the method, the simulated moving bed chromatography technology is a continuous process and is simple in technique, and easy to automate, and on the basis of ensuring the purity and productivity of the products, the solvent in the whole process can be recycled, and the low-cost and pollution-free production mode can be realized.

The invention relates to a countercurrent continuous chromatographic resolution method of a guaifenesin racemate. The method utilizes simulated moving bed chromatography to realize continuous separation and comprises one or more of a synchronous control process (SMB), an asynchronous control process (Varicol), a feed rate periodic change process (Powerfeed) and a feed concentration periodic change process (Modicon). When silica gel coated with cellulose-tris(3, 5-dimethylphenylcarbamate) is used as a chiral stationary phase and a mixture of n-hexane and ethanol is used as a mobile phase, the method can continuously and efficiently resolve a guaifenesin racemate, acquire a R-guaifenesin racemate enantiomer and a S-guaifenesin racemate enantiomer with high purity (greater than 99%) and meet the pharmaceutical market standards. The method has a high degree of production automation, high production efficiency and simple processes. In the whole process, the solvent can be recycled so that a cost is low and pollution is avoided.

The invention relates to a drug combination for relieving cough and reducing phlegm, which is composed of active constituents and a pharmaceutic adjuvant, wherein the active constituents comprise butamirate critrate, dextromethorphan hydrobromide and guaifenesin. The composition can be prepared into various kinds of oral preparations such as granules, troches, capsules, oral solution, syrup and the like and can be used for carrying out symptomatic treatment on related diseases with symptoms of cough, abundance of phlegm and the like.

The invention provides six liquid compositions containing phenylephrine hydrochloride. The six liquid compositions contain the following active substances: a composition 1: phenylephrine hydrochloride, brompheniramine maleate and dextromethorphan hydrobromide; a composition 2: phenylephrine hydrochloride, acetaminophen, guaiacol glyceryl ether and dextromethorphan hydrobromide; a composition 3: phenylephrine hydrochloride, chlorpheniramine maleate, acetaminophen and dextromethorphan hydrobromide; a composition 4: phenylephrine hydrochloride, acetaminophen and dextromethorphan hydrobromide; a composition 5: phenylephrine hydrochloride, acetaminophen and diphenhydramine hydrochloride; and a composition 6: phenylephrine hydrochloride, acetaminophen and guaiacol glyceryl ether. The inventor finds that the stability of the six liquid compositions is related to the pH value through research. The liquid composition can be used for treating respiratory diseases caused by cold, including virusinfection, such as influenza and cold, as well as allergy, sinusitis, rhinitis and the like.

The invention discloses a process for preparing Paracetamol dispersible tablets, which consists of granulating guaiphenesin carbamate and adjuvant, then granulating acetaminopher, d-pesudoephedrine hydrochloride, Dextromethorphan Hydrobromide and adjuvant, drying the two kinds of particles, finally mixing uniformly and moulding.

The invention discloses Guaifenesin and Dextromethorphan sustained release tablets and a preparation method thereof. The Guaifenesin and Dextromethorphan sustained release tablets are composed of dextromethorphan hydrobromide and guaifenesin. The guaifenesin is a phlegm-expelling agent, and is capable of reflexively promoting increase of respiratory tract gland secretion by stimulating gastric mucosa to cause slight nausea, phlegm is diluted and coughed up; dextromethorphan hydrobromide is a central antitussive agent, has detect effect on coughing center of medulla oblongata, can inhibit cough reaction, and generates no addition. The Guaifenesin and Dextromethorphan sustained release tablets are used for treating cough and expectoration due to upper respiratory infection and bronchitis; compared with various same kinds of the product, the Guaifenesin and Dextromethorphan sustained release tablets have dual efficacies of eliminating phlegm and relieving cough, has the advantages of definite therapeutic effect, stable quality, and convenient administration, and is an ideal selection for medicine capable of relieving cough and resolving phlegm.

The invention provides a drug composition with the active components of levodropropizine, guaifenesin and pseudoephedrine or acceptable salts on the drugs and a preparation method, which is used for treating nasopharynx mucosa hyperemia, nasal obstruction, sneeze, snivel caused by cold and other diseases, cough and expectoration and other symptoms caused by bronchitis. Compared with the common used centrally antitussive drugs on market, the peripherally antitussive drugs of levodropropizine adopted by the invention have the advantages of obvious antitussive effect and less adverse reaction.

The present invention discloses a kind of cough-relieving and phlegm-eliminating medicine composition, and is especially orally taken medicine composition dripping pill with guaiamar as active component. The guaiamar dripping pill has great medicine carrying amount, fast medicine releasing, fast acting, high bioavailability, less toxic side effect, convenient taking and low cost. The guaiamar dripping pill is prepared with guaiamar as active component, and through adding medicinal carrier as matrix, heating to obtain melt and / or emulsion and / or suspension of guaiamar and matrix, and dropping into condensating agent in dripping pill machine to form through shrinking.

The invention discloses a medicinal composition capable of relieving cough and reducing sputum and a production method thereof. The composition is especially used for treating cough symptoms in the diseases of the respiratory system, such as influenza, whooping cough, bronchitis, laryngitis and the like. A medicine prepared from the composition comprises the following effective components in unit dose: 0.01-20mg of pholcodine, 0.1-300mg of guaiphenesin and 0.01-20mg of maleic acid / or hydrochloride chlorpheniramine. The medicinal composition is an oral preparation. Compared with the similar medicine, the medicinal composition has the characteristics of small dosage, favorable curative effect, high safety and convenient taking.

The invention discloses medicine containing guaifenesin. The medicine containing the guaifenesin is safe and effective, and meets the taste of children better. Every 1000ml of the medicine comprises 18-22g of the guaifenesin, 2.7-3.3g of pseudoephedrine hydrochloride, 8.0-10.0g of sodium chloride, 4.0-5.0g of citric acid, 8.0-9.0g of sodium citrate, 0.9-1.1ml of fruit flavor essence, 220-260g of sorbitol, 36-44g of cane sugar, and the balance of water.

The invention discloses talcum powder-guaifenesin water-based polyurethane anticorrosive paint for rattan crafts. The water-based polyurethane anticorrosive paint is prepared from the following raw materials in parts by weight: 0.5 to 1 part of nanometer talcum powder, 0.5 to 1 part of guaifenesin, 0.1 to 0.15 part of cetyl pyridinium chloride, 10 to 15 parts of nanocellulose suspension with 10 to 12% of solid content, 0.3 to 0.5 part of guar gum, 40 to 50 parts of water-based polyurethane resin, 0.5 to 1 part of octenyl succinic anhydride, 4 to 6 parts of absolute ethyl alcohol, 0.3 to 0.5 part of potassium sorbate, 0.5 to 1 part of kathon preservative, and 0.3 to 0.5 part of water-soluble lanolin. The water-based polyurethane anticorrosive paint has the advantages that the anti-bacterial and anticorrosive properties are good, the toughness is high, the binding property with rattan fiber is good, the easiness in cracking and falling is avoided, the paint film is fine and smooth, the color is uniform, the appearance quality is high, and the sanitation and decoration properties are good.

The invention discloses a method for preparing methocarbamol. The method comprises the steps that guaifenesin serves as a raw material, alkali and 4-dimethylaminopyridine serve as a catalyst, carbonicester serves as an esterification agent, and a compound shown in the formula (I) is obtained through an esterification reaction, the compound shown in the formula (I) reacts with ammonia water through an ammoniation reaction to obtain the methocarbamol shown in the formula (II), and the reaction equation of the methocarbamol is that the alkali is hydroxide or carbonate of the first main alkali metal group. Accordingly, guaifenesin serves as a raw material, the alkali and DMAP serves as the catalyst, the carbonic ester is catalyzed to be esterified and then ammonified and crystallized, and themethocarbamol is obtained. A nucleophilic reagent DMAP is used for catalysis, the carbonic ester can rapidly and highly selectively complete the reaction with hydroxide radical, and the high-yield guaifenesin ester is obtained; in addition, the dosage of the carbonic ester is small, safety and environmental protection are achieved, pollution is small, the economic benefit is high, operation is easy, and the method is suitable for industrial production.